Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the ...

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

NYSE GMED opened at $83.99 on Friday. Globus Medical has a fifty-two week low of $49.33 and a fifty-two week high of $94.93. The stock has a market cap of $11.44 billion, a PE ratio of 125.36, a P ...